T-Therapeutics, a British BioTech company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announced the successful expansion of its Series A financing, raising a further €27.5 million ($32 million).
New investors Tencent and BGF joined the Series A syndicate, alongside all existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund.
Following the initial €50.7 million ($59 million) raised, this brings the Series A total to date to €78.2 million ($91 million).
Theodora Harold, CEO of T-Therapeutics, said: “Our transformative medicines tackle upstream disease-drivers that can have pan-indication impact. We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support.”
This Series A extension positions the UK-based BioTech within the broader 2025 European immuno-oncology funding landscape.
In France, Adcytherix secured €105 million to advance its antibody–drug conjugate pipeline, while Spain’s Adaptam Therapeutics raised €3 million to progress therapies targeting immunosuppressive myeloid cells.
Although these companies operate in adjacent rather than identical modalities, they collectively indicate persistent investor interest across European immunotherapy and oncology innovation in 2025.
Together, these rounds represent roughly €108 million of capital flowing through the sector, underscoring that T-Therapeutics’ cumulative €78.2 million Series A constitutes a significant proportion of visible activity this year.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, said: “The existing investors co-founded T-Therapeutics to push the boundaries of bispecific technology. This additional capital enables us to expand into T cell subset depletion, one of the most exciting areas in immunology, while continuing to advance oncology programmes.
“We are now ideally positioned to address both cancer and autoimmune disease, two broad disease areas with critical unmet medical needs, with a platform that unlocks targets previously considered undruggable.”
Founded in 2022, T-Therapeutics is a next-generation TTCR company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease.
T-Therapeutics’ team combines world-leading expertise in mouse genome engineering, single cell genomics, biopharmaceutical drug development, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
T-Therapeutics’ TCR platform, OpTiMus, can reportedly generate an almost unlimited repertoire of high specificity, fully human TCRs, enabling access to validated, but previously undruggable, intracellular targets.
The Company also leverages its proprietary next-generation CD3 T cell engagers (TCEs), which have been engineered for high potency, superior safety and favourable pharmacokinetics. OpTiMus-derived TCRs are combined with the proprietary TCEs to form first-in-class bispecific drug candidates.
T-Therapeutics’ pipeline is focused on upstream disease-drivers with pan-indication potential to deliver significant clinical benefit for patients.
Luke Rajah, Partner at BGF, added: “This is a leadership team with an outstanding track record of building successful drug discovery businesses and translating science into medicines. Backed by a syndicate of world-class life sciences investors, T-Therapeutics is uniquely positioned to unlock previously undruggable targets with its first-in-class bispecifics. We are proud to support the team and help catalyse their programmes towards the clinic.”
T-Therapeutics will use the additional proceeds to drive its pipeline of first-in-class TCR-CD3 bispecifics across oncology and autoimmune diseases towards the clinic, including the further exploration of new therapeutic strategies such as T cell subset depletion.
Their lead asset in oncology exploits a pan-tumour driver target, applicable across multiple different solid tumour types. Its lead immunology programme is a pan-autoimmune bispecific designed for precision immune reset, achieved by the selective depletion of pathogenic immune cells.
Read the orginal article: https://www.eu-startups.com/2025/11/cambridge-t-therapeutics-startup-secures-e27-5-million-to-improve-how-the-immune-system-targets-disease/
